Clovis Oncology 2017 J.P. Morgan Healthcare Conference

Clovis Oncology presented at the 35th Annual J.P. Morgan Healthcare Conference in January 2017, highlighting the December 2016 FDA approval of Rubraca (rucaparib), a PARP inhibitor for ovarian cancer. The presentation outlines the company's clinical development pipeline, including the ARIEL3 pivotal maintenance study expected to generate mid-2017 data, and discusses intellectual property protection through 2031-2035.